Entasis Therapeutics (NASDAQ:ETTX) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.
ETTX has been the subject of a number of other research reports. Zacks Investment Research upgraded Entasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright assumed coverage on Entasis Therapeutics in a research report on Monday, August 19th. They set a “buy” rating and a $18.00 price objective for the company.
NASDAQ:ETTX opened at $6.14 on Tuesday. The company has a quick ratio of 9.11, a current ratio of 9.11 and a debt-to-equity ratio of 0.03. The business’s 50-day simple moving average is $6.00 and its two-hundred day simple moving average is $6.46. The stock has a market cap of $81.43 million and a PE ratio of -0.50. Entasis Therapeutics has a 52 week low of $3.97 and a 52 week high of $9.25.
Entasis Therapeutics (NASDAQ:ETTX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($1.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.44). Sell-side analysts anticipate that Entasis Therapeutics will post -4.03 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Entasis Therapeutics stock. BlackRock Inc. increased its stake in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 29.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,657 shares of the company’s stock after acquiring an additional 3,784 shares during the period. BlackRock Inc. owned approximately 0.13% of Entasis Therapeutics worth $108,000 as of its most recent SEC filing. Institutional investors and hedge funds own 64.99% of the company’s stock.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
See Also: What factors cause inflation to rise?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.